

Wen-You Li*, Yong Song, Hong-Bo Chen and Wen-Long Yang

Synthesis of 2-amino-5-mercapto-1,3,4-thiadiazole derivatives

Abstract: 2-Amino-5-mercapto-1,3,4-thiadiazole (AMT) was used to synthesize 24 new compounds. The structures were confirmed by ^1H NMR and ^{13}C NMR.

Keywords: 2-amino-5-mercapto-1,3,4-thiadiazole; chloroacetyl chloride; heterocyclic.

*Corresponding author: Wen-You Li, Dalian University of Technology, Dalian 116012, P.R. China; and Department of Chemical Engineering, Jiuquan Vocational and Technical College, Jiuquan 735000, P.R. China, e-mail: jqzylwy@163.com

Yong Song and Hong-Bo Chen: Dalian University of Technology, Dalian 116012, P.R. China

Wen-Long Yang: Department of Chemical Engineering, Jiuquan Vocational and Technical College, Jiuquan 735000, P.R. China

Introduction

Recent drug studies are highly focused on heterocyclic ring systems. Thiadiazoles are one of the privileged structural fragments. Fused systems containing the thiadiazole ring give rise to compounds with varied bioactivities, such as anticancer [1], antimicrobial [2, 3], and antiviral [4] properties. Currently, compounds **A** [5] and **B** [6, 7] (Figure 1) are in clinical trials, and several other 1,3,4-thiadiazole derivatives including **C** [8, 9], **D** [10], and the parent compound 2-amino-5-mercapto-1,3,4-thiadiazole (AMT) [11–15] display a variety of biological activities. Several synthetic strategies to AMT have been reported [16]. The easy accessibility of AMT prompted us to prepare a new series of 2-amino-5-mercapto-1,3,4-thiadiazole derivatives.

Results and discussion

First, the Michael addition reaction of AMT with α,β -unsaturated compounds was studied. With acrylonitrile as the substrate, the products **1a** and **2a** were obtained in the respective yields of 47% and 49% under optimal conditions. This reaction was studied using EtOH, acetone,

DMSO, water, and MeOH. The results indicated that MeOH is the optimal solvent. The reaction hardly proceeded in the remaining solvents. The highest yields of **1a** and **2a** were obtained in the presence of triethylamine, lower yields were obtained in the presence of EtONa, and no products were detected in the attempted reactions in the presence of NaOH or NaHCO_3 . Products **1b,c** and **2b,c** were prepared in a similar manner by subjecting AMT to the Michael addition with methyl acrylate and butyl acrylate (Scheme 1).

Then, our attention focused on the acylation reaction of **1a–c** and **2a–c** with chloroacetyl chloride, which yielded the respective derivatives **3a–c** and **4a–c**. These products were cyclized to two different rings by the reaction with potassium isothiocyanate. The imidazole derivatives **5a–c** and **7a–c** are formed in the reaction with KSCN conducted in acetonitrile, and the thiazole derivatives **6a–c** and **8a–c** are obtained in DMF at 80°C . A unified mechanism that accounts for these two different outcomes is proposed in Scheme 2.






Figure 1 Selected biologically active 1,3,4-thiadiazole derivatives.



Scheme 1



Scheme 2

Experimental

General

Melting points were determined on a Perkin-Elmer differential scanning calorimeter and are uncorrected. The IR spectra were run on a Nicolette spectrometer using KBr pellets. NMR spectra were recorded at 400 MHz (¹H) and 100 MHz (¹³C) on a Varian Mercury plus-400 instrument.

General procedure for synthesis of compounds 1a–c and 2a–c

Triethylamine (0.6 mL, 0.86 mmol) was slowly added to a solution of AMT (0.66 g, 5 mmol), acrylonitrile, methyl acrylate or butyl acrylate (2 mmol) in CH₃OH (50 mL) under nitrogen, and the mixture was

heated under reflux for 4–8 h. After cooling, the mixture was concentrated under reduced pressure, and the residue was purified by silica gel chromatography eluting with dichloromethane/methanol (95:5) to give starting AMT followed by the products **1a–c** and **2a–c**.

3-(5-Amino-2-thioxo-1,3,4-thiadiazol-3(2H)-yl)propanenitrile (1a) Yield 47%; mp 103–105°C; IR (cm^{−1}): 3415, 3284, 2173, 1619, 1553, 1182, 1066; ¹H NMR (CDCl₃): δ 3.04 (t, *J* = 7 Hz, 2H), 4.41 (t, *J* = 7 Hz, 2H), 6.68 (s, 2H). Anal. Calcd for C₅H₆N₄S₂: C, 32.24; H, 3.25; N, 30.08; S, 34.43. Found: C, 32.22; H, 3.26; N, 30.07; S, 34.45.

Methyl 3-(5-amino-2-thioxo-1,3,4-thiadiazol-3(2H)-yl)propanoate (1b) Yield 29%; mp 119–121°C; IR (cm^{−1}): 3416, 3285, 2924, 1718, 1620, 1556, 1213, 1068; ¹H NMR (CDCl₃): δ 2.82 (t, *J* = 7 Hz, 2H), 3.64 (s, 3H), 4.36 (t, *J* = 7 Hz, 2H), 6.60 (s, 2H). Anal. Calcd for C₆H₉N₃O₂S₂: C, 32.86; H, 4.14; N, 19.16; O, 14.59; S, 29.25. Found: C, 32.88; H, 4.13; N, 19.18; O, 14.57; S, 29.23.

Butyl 3-(5-amino-2-thioxo-1,3,4-thiadiazol-3(2H)-yl)propanoate (1c) Yield 17%; red brown foam; IR (cm^{−1}): 3315, 3191, 2959, 1724, 1559, 1256, 1184, 1068; ¹H NMR (CDCl₃): δ 0.92 (t, *J* = 8 Hz, 3H), 1.41 (m, *J* = 8 Hz, 2H), 1.61 (m, *J* = 8 Hz, 2H), 2.83 (t, *J* = 8 Hz, 2H), 4.07 (t, *J* = 8 Hz, 2H), 4.37 (t, *J* = 8 Hz, 2H), 6.55 (s, 2H). Anal. Calcd for C₉H₁₅N₃O₂S₂: C, 41.36; H, 5.78; N, 16.08; O, 12.24; S, 24.54. Found: C, 41.37; H, 5.76; N, 16.06; O, 12.23; S, 24.56.

3-[(5-Amino-1,3,4-thiadiazol-2-yl)thio]propanenitrile (2a) Yield 49%; mp 136–137°C; IR (cm^{−1}): 3297, 3102, 2170, 1631, 1579, 1504, 1068; ¹H NMR (CDCl₃): δ 2.93 (t, *J* = 7 Hz, 2H), 3.33 (t, *J* = 7 Hz, 2H), 7.38 (s, 2H). Anal. Calcd for C₅H₆N₄S₂: C, 32.24; H, 3.25; N, 30.08; S, 34.43. Found: C, 32.25; H, 3.27; N, 30.09; S, 34.44.

Methyl 2-[(5-amino-1,3,4-thiadiazol-2-yl)thio]propanoate (2b) Yield 58%; mp 102–104°C; IR (cm^{−1}): 3311, 3101, 2926, 1728, 1633, 1503, 1246, 1066; ¹H NMR (CDCl₃): δ 2.81 (t, *J* = 7 Hz, 2H), 3.34 (t, *J* = 7 Hz, 2H), 3.65 (s, 3H), 6.64 (s, 2H). Anal. Calcd for C₆H₉N₃O₂S₂: C, 32.86; H, 4.14; N, 19.16; O, 14.59; S, 29.25. Found: C, 32.88; H, 4.13; N, 19.18; O, 14.57; S, 29.23.

4.14; N, 19.16; O, 14.59; S, 29.25. Found: C, 32.85; H, 4.16; N, 19.17; O, 14.60; S, 29.26.

Butyl 2-[(5-amino-1,3,4-thiadiazol-2-yl)thio]propanoate (2c) Yield 42%; mp 93–95°C, IR (cm⁻¹): 3298, 3102, 2958, 1723, 1502, 1247, 1066; ¹H NMR (CDCl₃): δ 0.92 (t, *J* = 7 Hz, 3H), 1.38 (m, *J* = 7 Hz, 2H), 1.58 (m, *J* = 7 Hz, 2H), 2.80 (t, *J* = 7 Hz, 2H), 3.34 (t, *J* = 7 Hz, 2H), 4.08 (t, *J* = 7 Hz, 2H), 6.60 (s, 2H). Anal. Calcd for C₉H₁₅N₃O₃S₂: C, 41.36; H, 5.78; N, 16.08; O, 12.24; S, 24.54. Found: C, 41.35; H, 5.79; N, 16.07; O, 12.27; S, 24.51.

General procedure for synthesis of compounds 3a–c and 4a–c

Chloroacetyl chloride (2 mmol) was added dropwise to a stirred cold solution (0°C) of **1a–c** or **2a–c** (1 mmol) in DMF (3 mL) and the mixture was stirred at room temperature for an additional 8 h. After concentration under reduced pressure, the residue was crystallized from ethanol.

2-Chloro-*N*-(4-(2-cyanoethyl)-5-thioxo-4,5-dihydro-1,3,4-thiadiazol-2-yl)acetamide (3a) Yield 61%; mp 164–167°C; IR (cm⁻¹): 3439, 2926, 2221, 1712, 1569, 1556, 1079. Anal. Calcd for C₇H₇ClN₄OS₂: C, 32.00; H, 2.69; Cl, 13.49; N, 21.32; O, 6.09; S, 24.41. Found: C, 32.02; H, 2.70; Cl, 13.50; N, 21.33; O, 6.08; S, 24.42.

Methyl 3-(5-(2-chloroacetamido)-2-thioxo-1,3,4-thiadiazol-3(2H)-yl)propanoate (3b) Yield: 88%; mp 112–116°C, IR (cm⁻¹): 3441, 2917, 1710, 1691, 1582, 1212, 1183, 1075. Anal. Calcd for C₈H₁₀ClN₃O₃S₂: C, 32.49; H, 3.41; Cl, 11.99; N, 14.21; O, 16.23; S, 21.68. Found: C, 32.50; H, 3.43; Cl, 11.97; N, 14.20; O, 16.25; S, 21.69.

Butyl 3-(5-(2-chloroacetamido)-2-thioxo-1,3,4-thiadiazol-3(2H)-yl)propanoate (3c) Yield 87%; mp 92–94°C, IR (cm⁻¹): 3432, 2929, 1729, 1709, 1579, 1213, 1184, 1080. Anal. Calcd for C₁₁H₁₆ClN₃O₃S₂: C, 39.11; H, 4.77; Cl, 10.49; N, 12.44; O, 14.21; S, 18.98. Found: C, 39.13; H, 4.75; Cl, 10.50; N, 12.42; O, 14.23; S, 19.00.

2-Chloro-*N*-[5-((2-cyanoethyl)thio)-1,3,4-thiadiazol-2-yl]acetamide (4a) Yield 91%; mp 174–178°C, IR (cm⁻¹): 3439, 2925, 2230, 1707, 1582, 1065. Anal. Calcd for C₇H₇ClN₄OS₂: C, 32.00; H, 2.69; Cl, 13.49; N, 21.32; O, 6.09; S, 24.41. Found: C, 31.98; H, 2.67; Cl, 13.51; N, 21.30; O, 6.10; S, 24.43.

Methyl 3-[(5-(2-chloroacetamido)-1,3,4-thiadiazol-2-yl)thio]propanoate (4b) Yield 93%; mp 144–145°C, IR (cm⁻¹): 3439, 2946, 1734, 1706, 1587, 1197, 1177, 1069. Anal. Calcd for C₈H₁₀ClN₃O₃S₂: C, 32.49; H, 3.41; Cl, 11.99; N, 14.21; O, 16.23; S, 21.68. Found: C, 32.47; H, 3.43; Cl, 12.01; N, 14.23; O, 16.21; S, 21.67.

Butyl 3-[(5-(2-chloroacetamido)-1,3,4-thiadiazol-2-yl)thio]propanoate (4c) Yield 83%; mp 105–106°C, IR (cm⁻¹): 3435, 2961, 1729, 1704, 1577, 1296, 1183, 1065. Anal. Calcd for C₁₁H₁₆ClN₃O₃S₂: C, 39.11; H, 4.77; Cl, 10.49; N, 12.44; O, 14.21; S, 18.98. Found: C, 39.10; H, 4.79; Cl, 10.51; N, 12.42; O, 14.20; S, 18.97.

General procedure for synthesis of compounds 5a–c and 7a–c

A solution of **3a–c** or **4a–c** (1 mmol) in acetonitrile (3 mL) was treated with tetrabutylammonium bromide (TBAB, 0.1 g) and KI (0.11 g,

0.66 mmol) and the mixture was stirred for 15 min at room temperature. After addition of KSCN (0.1 g, 1 mmol), the mixture was heated to 80°C for 1 h, then cooled and concentrated under reduced pressure. The residue was purified by silica gel chromatography eluting with dichloromethane/methanol (95:5).

3-[5-(5-Oxo-2-thioxoimidazolidin-1-yl)-2-thioxo-1,3,4-thiadiazol-3(2H)-yl]propanenitrile (5a) Yield 56%; mp 162°C, IR (cm⁻¹): 3432, 2273, 1749, 1625, 1571, 1175, 1083; ¹H NMR (CDCl₃): δ 3.16 (t, *J* = 7 Hz, 2H), 4.18 (s, 2H), 4.61 (t, *J* = 7 Hz, 2H), 11.05 (s, 1H). Anal. Calcd for C₈H₇N₅OS₃: C, 33.67; H, 2.47; N, 24.54; O, 5.61; S, 33.71. Found: C, 33.69; H, 2.45; N, 24.51; O, 5.63; S, 33.68.

Methyl 3-[5-(5-oxo-2-thioxoimidazolidin-1-yl)-2-thioxo-1,3,4-thiadiazol-3(2H)-yl]propanoate (5b) Yield 50%; mp 103–104°C, IR (cm⁻¹): 3420, 2922, 1738, 1582, 1251, 1184, 1078; ¹H NMR (CDCl₃): δ 2.95 (t, *J* = 7 Hz, 2H), 3.67 (s, 3H), 4.16 (s, 2H), 4.52 (t, *J* = 7 Hz, 2H), 10.91 (s, 1H). Anal. Calcd for C₉H₁₀N₄O₃S₃: C, 33.95; H, 3.17; N, 17.60; O, 15.08; S, 30.21. Found: C, 33.94; H, 3.19; N, 17.59; O, 15.10; S, 30.23.

Butyl 3-[5-(5-oxo-2-thioxoimidazolidin-1-yl)-2-thioxo-1,3,4-thiadiazol-3(2H)-yl]propanoate (5c) Yield 43%; mp 132–134°C, IR (cm⁻¹): 3429, 2957, 1748, 1633, 1589, 1266, 1179, 1084; ¹H NMR (400 MHz, CDCl₃): δ 0.93 (t, *J* = 7 Hz, 3H), 1.40 (m, *J* = 7 Hz, 2H), 1.60 (m, *J* = 7 Hz, 2H), 2.95 (t, *J* = 7 Hz, 2H), 4.07 (t, *J* = 7 Hz, 2H), 4.10 (s, 2H), 4.52 (t, *J* = 7 Hz, 2H), 11.00 (s, 1H). Anal. Calcd for C₁₂H₁₆N₄O₃S₃: C, 39.98; H, 4.47; N, 15.54; O, 13.32; S, 26.69. Found: C, 39.95; H, 4.49; N, 15.55; O, 13.30; S, 26.70.

3-[(5-(5-Oxo-2-thioxoimidazolidin-1-yl)-1,3,4-thiadiazol-2-yl)thio]propanenitrile (7a) Yield 67%; mp 196–198°C; IR (cm⁻¹): 3451, 2230, 1734, 1569, 1166, 1053; ¹H NMR (CDCl₃): δ 3.10 (t, *J* = 7 Hz, 2H), 3.63 (t, *J* = 7 Hz, 2H), 4.11 (s, 2H), 10.90 (s, 1H). Anal. Calcd for C₈H₇N₅OS₃: C, 33.67; H, 2.47; N, 24.54; O, 5.61; S, 33.71. Found: C, 33.68; H, 2.49; N, 24.53; O, 5.60; S, 33.70.

Methyl 3-[(5-(5-oxo-2-thioxoimidazolidin-1-yl)-1,3,4-thiadiazol-2-yl)thio]propanoate (7b) Yield 75%; mp 165–167°C, IR (cm⁻¹): 3448, 2923, 1734, 1595, 1174, 1073; ¹H NMR (CDCl₃): δ 2.89 (t, *J* = 7 Hz, 2H), 3.53 (t, *J* = 7 Hz, 2H), 3.67 (s, 3H), 4.10 (s, 2H), 10.90 (s, 1H). Anal. Calcd for C₉H₁₀N₄O₃S₃: C, 33.95; H, 3.17; N, 17.60; O, 15.08; S, 30.21. Found: C, 33.96; H, 3.18; N, 17.61; O, 15.07; S, 30.22.

Butyl 3-[(5-(5-oxo-2-thioxoimidazolidin-1-yl)-1,3,4-thiadiazol-2-yl)thio]propanoate (7c) Yield 42%; mp 110–113°C, IR (cm⁻¹): 3432, 2961, 1734, 1598, 1259, 1175, 1090; ¹H NMR (CDCl₃): δ 0.92 (t, *J* = 7 Hz, 3H), 1.40 (m, *J* = 7 Hz, 2H), 1.61 (m, *J* = 7 Hz, 2H), 2.89 (t, *J* = 7 Hz, 2H), 3.53 (t, *J* = 7 Hz, 2H), 4.10 (t, *J* = 7 Hz, 2H), 4.10 (s, 2H), 10.89 (s, 1H). Anal. Calcd for C₁₂H₁₆N₄O₃S₃: C, 39.98; H, 4.47; N, 15.54; O, 13.32; S, 26.69. Found: C, 39.97; H, 4.46; N, 15.57; O, 13.33; S, 26.67.

General procedure for synthesis of compounds 6a–c and 8a–c

A solution of **3a–c** or **4a–c** (1 mmol) in DMF (2 mL) was treated with KI (0.11 g, 0.66 mmol) and KSCN (0.1 g, 1 mmol) and the mixture was heated to 100°C for 1 h. After cooling and concentration under reduced pressure, the residue was crystallized from 80% aqueous ethanol.

3-[5-((4-Oxothiazolidin-2-ylidene)amino)-2-thioxo-1,3,4-thiadiazol-3(2H)-yl]propanenitrile (6a) Yield 71%; mp 206–208°C, IR (cm⁻¹): 3437, 2924, 2253, 1747, 1623, 1173, 1082; ¹H NMR (DMSO-*d*₆): δ 3.110 (t, *J* = 6 Hz, 2H), 4.17 (s, 2H), 4.49 (t, *J* = 6 Hz, 2H), 12.48 (s, 1H). Anal. Calcd for C₈H₇N₅O₃S: C, 33.67; H, 2.47; N, 24.54; O, 5.61; S, 33.71. Found: C, 33.66; H, 2.45; N, 24.55; O, 5.59; S, 33.72.

Methyl 3-[5-((4-oxothiazolidin-2-ylidene)amino)-2-thioxo-1,3,4-thiadiazol-3(2H)-yl]propanoate (6b) Yield 71%; mp 161°C, IR (cm⁻¹): 3432, 2939, 1738, 1581, 1252, 1185, 1079; ¹H NMR (DMSO-*d*₆): δ 2.90 (t, *J* = 7 Hz, 2H), 3.615 (s, 3H), 4.15 (s, 2H), 4.42 (t, *J* = 7 Hz, 2H), 12.43 (s, 1H). Anal. Calcd for C₉H₁₀N₄O₃S₂: C, 33.95; H, 3.17; N, 17.60; O, 15.08; S, 30.21. Found: C, 33.94; H, 3.16; N, 17.64; O, 15.05; S, 30.23.

Butyl 3-[5-((4-oxothiazolidin-2-ylidene)amino)-2-thioxo-1,3,4-thiadiazol-3(2H)-yl]propanoate (6c) Yield 61%; mp 154–155°C, IR (cm⁻¹): 3432, 2960, 1726, 1634, 1575, 1244, 1181, 1082; ¹H NMR (DMSO-*d*₆): δ 0.86 (t, *J* = 7 Hz, 3H), 1.28 (m, *J* = 7 Hz, 2H), 1.54 (m, *J* = 7 Hz, 2H), 2.90 (t, *J* = 7 Hz, 2H), 4.02 (t, *J* = 7 Hz, 2H), 4.15 (s, 2H), 4.42 (t, *J* = 7 Hz, 2H), 12.44 (s, 1H). Anal. Calcd for C₁₂H₁₆N₄O₃S₂: C, 39.98; H, 4.47; N, 15.54; O, 13.32; S, 26.69. Found: C, 39.99; H, 4.45; N, 15.53; O, 13.34; S, 26.68.

3-[5-((4-Oxothiazolidin-2-ylidene)amino)-1,3,4-thiadiazol-2-yl]thio]propanenitrile (8a) Yield 63%; mp 208–210°C, IR (cm⁻¹): 3432,

2933, 2245, 1735, 1651, 1561, 1168; ¹H NMR (400 MHz, DMSO): δ 3.05 (t, *J* = 6 Hz, 2H), 3.55 (t, *J* = 6 Hz, 2H), 4.11 (s, 2H), 12.35 (s, 2H). Anal. Calcd for C₈H₇N₅O₃S: C, 33.67; H, 2.47; N, 24.54; O, 5.61; S, 33.71. Found: C, 33.69; H, 2.43; N, 24.57; O, 5.59; S, 33.70.

Methyl 3-[5-((4-oxothiazolidin-2-ylidene)amino)-1,3,4-thiadiazol-2-yl]thio]propanoate (8b) Yield 65%; mp 176–177°C, IR (cm⁻¹): 3430, 2924, 1732, 1597, 1251, 1173, 1071; ¹H NMR (DMSO-*d*₆): δ 2.85 (t, *J* = 7 Hz, 2H), 3.45 (t, *J* = 7 Hz, 2H), 3.63 (s, 3H), 4.11 (s, 2H), 12.33 (s, 1H). Anal. Calcd for C₉H₁₀N₄O₃S₂: C, 33.95; H, 3.17; N, 17.60; O, 15.08; S, 30.21. Found: C, 33.97; H, 3.19; N, 17.62; O, 15.07; S, 30.20.

Butyl 3-[5-((4-oxothiazolidin-2-ylidene)amino)-1,3,4-thiadiazol-2-yl]thio]propanoate (8c) Yield 72%; mp 111–112°C, IR (cm⁻¹): 3405, 2958, 1732, 1594, 1171, 1248, 1056; ¹H NMR (DMSO-*d*₆): δ 0.88 (t, *J* = 8 Hz, 3H), 1.33 (m, *J* = 8 Hz, 2H), 1.55 (m, *J* = 8 Hz, 2H), 2.84 (t, *J* = 8 Hz, 2H), 3.45 (t, *J* = 8 Hz, 2H), 4.05 (t, *J* = 8 Hz, 2H), 4.11 (s, 2H), 12.33 (s, 1H). Anal. Calcd for C₁₂H₁₆N₄O₃S₂: C, 39.98; H, 4.47; N, 15.54; O, 13.32; S, 26.69. Found: C, 40.00; H, 4.46; N, 15.57; O, 13.30; S, 26.70.

Received November 3, 2013; accepted November 19, 2013

References

- [1] Karki, S. S.; Panjamurthy, K.; Kumar, S.; Nambiar, M.; Ramareddy, S. A.; Chiruvella, K. K.; Raghavan, S. C. Synthesis and biological evaluation of novel 2-aryl-5-substituted-6-(4-fluorophenyl)-imidazo[2,1-*b*][1,3,4]thiadiazole derivatives as potent anticancer agents. *Eur. J. Med. Chem.* **2011**, *46*, 2109–2116.
- [2] Lamani, R. S.; Shetty, N. S.; Kamble, R. R.; Khazi, I. A. M. Synthesis and antimicrobial studies of novel methylene bridged benzisoxazolyl imidazo[2,1-*b*][1,3,4]thiadiazole derivatives. *Eur. J. Med. Chem.* **2009**, *44*, 2828–2833.
- [3] Almajan, G. L.; Barbuceanu, S.-F.; Bancescu, G.; Saramet, I.; Saramet, G.; Draghici, C. Synthesis and antimicrobial evaluation of some fused heterocyclic [1,2,4]triazolo[3,4-*b*][1,3,4]thiadiazole derivatives. *Eur. J. Med. Chem.* **2010**, *45*, 6139–6146.
- [4] Kritsanida, M.; Mouroutsou, A.; Marakos, P.; Pouli, N.; Papakonstantinou-Garoufalias, S.; Pannecouque, C.; Witvrouw, M.; De Clercq, E. Synthesis and antiviral activity evaluation of some new 6-substituted 3-(1-adamantyl)-1,2,4-triazolo[3,4-*b*][1,3,4]thiadiazoles. *Farmaco* **2002**, *57*, 253–257.
- [5] Talath, S.; Gadad, A. K. Synthesis, antibacterial and antitubercular activities of some 7-[4-(5-amino-[1,3,4]thiadiazole-2-sulfonyl)-piperazin-1-yl]-fluoroquinolonic derivatives. *Eur. J. Med. Chem.* **2006**, *41*, 918–924.
- [6] Alireza, F.; Fatemeh, S.; Hamideh, M. H.; Abbas, S. Synthesis, in vitro-antimycobacterial activity and cytotoxicity of some alkyl α-(5-aryl-1,3,4-thiadiazole-2-yl-thio) acetates. *Arch. Pharm. Chem. Life Sci.* **2005**, *338*, 112–116.
- [7] Luo, Z. H.; Chen, B. Q.; He, S. Y.; Shi, Y. P.; Liu, Y. M.; Li, C. W. Synthesis and antitumor-evaluation of 1,3,4-thiadiazole-containing benzoselenazalone derivatives. *Bioorg. Med. Chem. Lett.* **2012**, *22*, 3191–3193.
- [8] Zhao, J.; Chen, B. Q.; Shi, Y. P.; Liu, Y. M.; Zhao, H. C.; Cheng, J. Synthesis and in vitro antitumor activity of 1,3,4-thiadiazole derivatives based on benzoselenazalone. *Chinese. Chem. Lett.* **2012**, *23*, 817–819.
- [9] Luo, Y.; Zhang, S.; Liu, Z. J.; Chen, W.; Fu, J.; Zeng, Q. F.; Zhu, H. L. Synthesis and antimicrobial evaluation of a novel class of 1,3,4-thiadiazole: derivatives bearing 1,2,4-triazolo[1,5-*a*]pyrimidine moiety. *Eur. J. Med. Chem.* **2013**, *64*, 54–61.
- [10] Li, Q.; Ren, J. M.; Dong, F.; Feng, Y.; Gu, G. D.; Guo, Z. Y. Synthesis and antifungal activity of thiadiazole-functionalized chitosan derivatives. *Carbohydr. Res.* **2013**, *373*, 103–107.
- [11] Wu, C. J.; Li, H.; Hasan, R. The chemopreventive effect of β-cryptoxanthin from mandarin on human stomach cells (BGC-823). *Food Chem.* **2013**, *136*, 1122–1129.
- [12] Zhang, Z. F.; Guo, Y.; Zhang, L. W.; Zhang, J. B.; Wei, X. H. Chelerythrine chloride from *Macleaya cordata* induces growth inhibition and apoptosis in human gastric cancer BGC-823 cells. *Acta Pharm. Sin. B.* **2012**, *5*, 464–471.
- [13] Sun, B.; Geng, S.; Huang, X. J.; Zhu, J.; Liu, S.; Zhang, Y. J.; Ye, J.; Li, Y. J.; Wang, J. Z. Coleusin factor exerts cytotoxic activity by inducing G0/G1 cell cycle arrest and apoptosis in human gastric cancer BGC-823 cells. *Cancer Lett.* **2011**, *301*, 95–105.
- [14] Jayakumar, S.; Kunwar, A.; Sandur, S. K.; Pandey, B. N.; Chaubey, R. C. Differential response of DU145 and PC3 prostate cancer cells to ionizing radiation: role of reactive oxygen species, GSH and Nrf2 in radiosensitivity. *Biochim. Biophys. Acta* **2014**, *1840*, 485–494.
- [15] Monteverde, M.; Tonissi, F.; Fischel, J.-L.; Etienne-Grimaldi, M.-C.; Milano, G.; Merlano, M.; Lo Nigro, C. Combination of docetaxel and vandetanib in docetaxel-sensitive or resistant PC₃ cell line. *Urol. Oncol.* **2013**, *31*, 776–786.
- [16] Shen, L.-H.; Li, H.-Y.; Shang, H.-X. Synthesis and cytotoxic evaluation of new colchicine derivatives bearing 1,3,4-thiadiazole moieties. *Chinese Chem. Lett.* **2013**, *24*, 299–302.